Skip to main content
Top
Published in: AIDS Research and Therapy 1/2020

Open Access 01-12-2020 | Human Immunodeficiency Virus | Research

Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4+:CD8+ T-cell ratio in treated HIV-1 infection

Authors: Inês T. Freitas, Willard Tinago, Hirofumi Sawa, Julie McAndrews, Brenda Doak, Charlotte Prior-Fuller, Gerard Sheehan, John S. Lambert, Eavan Muldoon, Aoife G. Cotter, William W. Hall, Patrick W. G. Mallon, Michael J. Carr

Published in: AIDS Research and Therapy | Issue 1/2020

Login to get access

Abstract

Background

The objectives of this study were to investigate the relationships between polymorphisms at the interferon lambda (IFNL) locus and CD4+:CD8+ ratio normalisation in people living with HIV (PLWH) on effective antiretroviral therapy (ART); and to examine whether these polymorphisms influence the composition of T lymphocyte compartments in long-term treated HIV-1 infection.

Methods

A cross-sectional study in PLWH enrolled into the Mater Immunology study. We performed IFNL genotyping on stored samples and evaluated the association of IFNL single-nucleotide polymorphisms (rs368234815 and rs12979860) with CD4+:CD8+ ratio normalization (> 1) and expanded CD4+ and CD8+ T-cell subsets; CD45RO+CD62L+ (central-memory), CD45RO+ CD62L(effector-memory) and CD45ROCD62L+ (naïve), using logistic and linear regression models, respectively.

Results

190 ambulatory PLWH recruited to the main study, 143 were included in the analysis (38 had no stored DNA and 9 no T-lymphocyte subpopulation). Of 143 included, the median age (IQR) was 45(39–48) years, 64% were male and 66% were of Caucasian ethnicity. Heterosexual-contact (36%), injecting drug-use (33%) and men who have sex with men (24%) were the most presented HIV-transmission risk groups. The majority of subjects (90.2%) were on ART with 79% of the cohort having an undetectable HIV-RNA (< 40 copies/ml) and the time since ART initiation was 7.5 (3.7–10.4) year. rs368234815 and rs12979860 displayed similar allelic frequencies, with minor alleles ΔG and T representing 39% and 42%, respectively, of circulating alleles. rs368234815 ΔG/ΔG minor homozygotes were significantly associated with increased odds for attaining a normalised CD4+:CD8+ ratio compared to rs368234815 T/T major homozygotes in PLWH virologically suppressed on effective ART (OR = 3.11; 95% CI [1.01:9.56]). rs368234815 ΔG/ΔG homozygosity was also significantly associated with lower levels of CD4+ effector memory T-cells (regression coefficient: − 7.1%, p = 0.04) and CD8+ naïve T-cell subsets were significantly higher in HIV-1 mono-infected PLWH with rs368234815 ΔG/ΔG (regression coefficient: + 7.2%, p = 0.04).

Conclusions

In virally-suppressed, long-term ART-treated PLWH, rs368234815 ΔG/ΔG homozygotes were more likely to have attained normalisation of their CD4+:CD8+ ratio, displayed lower CD4+ effector memory and higher naive CD8+ T-cells. Further studies are needed to replicate our findings in other, larger and more diverse cohorts and to determine the impact of IFNL genetic-variation on CD4+:CD8+ ratio normalisation and clinical outcomes in PLWH.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2(3):e98–106.CrossRef Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2(3):e98–106.CrossRef
2.
go back to reference Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol. 2011;186(4):2106–16.CrossRef Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol. 2011;186(4):2106–16.CrossRef
3.
go back to reference Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 2016;30(6):899–908.CrossRef Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 2016;30(6):899–908.CrossRef
4.
go back to reference Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, et al. Determinants of a low CD4/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression. Clin Infect Dis. 2016;62:1297–303.CrossRef Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, et al. Determinants of a low CD4/CD8 ratio in HIV-1-infected individuals despite long-term viral suppression. Clin Infect Dis. 2016;62:1297–303.CrossRef
5.
go back to reference Brites-Alves C, Netto EM, Brites C. Coinfection by hepatitis C is strongly associated with abnormal CD4/CD8 ratio in HIV patients under stable ART in Salvador, Brazil. J Immunol Res. 2015;2015:174215.CrossRef Brites-Alves C, Netto EM, Brites C. Coinfection by hepatitis C is strongly associated with abnormal CD4/CD8 ratio in HIV patients under stable ART in Salvador, Brazil. J Immunol Res. 2015;2015:174215.CrossRef
6.
go back to reference Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-Cell counts. Clin Infect Dis. 2016;62(2):250–7.CrossRef Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-Cell counts. Clin Infect Dis. 2016;62(2):250–7.CrossRef
7.
go back to reference Bellissimo F, Pinzone MR, Celesia BM, Cacopardo B, Nunnari G. Baseline CD4/CD8 T-cell ratio predicts prompt immune restoration upon cART initiation. Curr HIV Res. 2016;14:491–6.CrossRef Bellissimo F, Pinzone MR, Celesia BM, Cacopardo B, Nunnari G. Baseline CD4/CD8 T-cell ratio predicts prompt immune restoration upon cART initiation. Curr HIV Res. 2016;14:491–6.CrossRef
8.
go back to reference De Salvador-Guillouet F, Sakarovitch C, Durant J, Risso K, Demonchy E, Roger PM, et al. Antiretroviral regimens and CD4/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study. PLoS ONE. 2015;10(10):e0140519.CrossRef De Salvador-Guillouet F, Sakarovitch C, Durant J, Risso K, Demonchy E, Roger PM, et al. Antiretroviral regimens and CD4/CD8 ratio normalization in HIV-infected patients during the initial year of treatment: a cohort study. PLoS ONE. 2015;10(10):e0140519.CrossRef
9.
go back to reference Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naive and memory T-cell subsets. PLoS ONE. 2014;9(5):e97011.CrossRef Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naive and memory T-cell subsets. PLoS ONE. 2014;9(5):e97011.CrossRef
10.
go back to reference Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.CrossRef Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.CrossRef
11.
go back to reference Tang J, Li X, Price MA, Sanders EJ, Anzala O, Karita E, et al. CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data. Front Microbiol. 2015;6:670.PubMedPubMedCentral Tang J, Li X, Price MA, Sanders EJ, Anzala O, Karita E, et al. CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data. Front Microbiol. 2015;6:670.PubMedPubMedCentral
12.
go back to reference Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, et al. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. AIDS. 2015;29(12):1505–10.CrossRef Zaegel-Faucher O, Bregigeon S, Cano CE, Obry-Roguet V, Nicolino-Brunet C, Tamalet C, et al. Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy. AIDS. 2015;29(12):1505–10.CrossRef
13.
go back to reference Joshi A, Sedano M, Beauchamp B, Punke EB, Mulla ZD, Meza A, et al. HIV-1 Env glycoprotein phenotype along with immune activation determines CD4 T cell loss in HIV patients. J Immunol. 2016;196(4):1768–79.CrossRef Joshi A, Sedano M, Beauchamp B, Punke EB, Mulla ZD, Meza A, et al. HIV-1 Env glycoprotein phenotype along with immune activation determines CD4 T cell loss in HIV patients. J Immunol. 2016;196(4):1768–79.CrossRef
14.
go back to reference Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRef Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.CrossRef
15.
go back to reference Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.CrossRef Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.CrossRef
16.
go back to reference Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.CrossRef Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.CrossRef
17.
go back to reference Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.CrossRef Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.CrossRef
18.
go back to reference Collison M, Chin JL, Abu Shanab A, Mac Nicholas R, Segurado R, Coughlan S, et al. Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-alpha and ribavirin in chronic hepatitis C virus genotype 1 infection. J Interferon Cytokine Res. 2015;35(2):126–33.CrossRef Collison M, Chin JL, Abu Shanab A, Mac Nicholas R, Segurado R, Coughlan S, et al. Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-alpha and ribavirin in chronic hepatitis C virus genotype 1 infection. J Interferon Cytokine Res. 2015;35(2):126–33.CrossRef
19.
go back to reference Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology. 2010;139(5):1794–6.CrossRef Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology. 2010;139(5):1794–6.CrossRef
20.
go back to reference Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.CrossRef Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.CrossRef
21.
go back to reference Ye L, Schnepf D, Staeheli P. Interferon-lambda orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–25.CrossRef Ye L, Schnepf D, Staeheli P. Interferon-lambda orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–25.CrossRef
22.
go back to reference Ye L, Schnepf D, Becker J, Ebert K, Tanriver Y, Bernasconi V, et al. Interferon-lambda enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat Immunol. 2019;20(5):593–601.CrossRef Ye L, Schnepf D, Becker J, Ebert K, Tanriver Y, Bernasconi V, et al. Interferon-lambda enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat Immunol. 2019;20(5):593–601.CrossRef
23.
go back to reference Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H, et al. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS. 2014;28(13):1885–9.CrossRef Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H, et al. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS. 2014;28(13):1885–9.CrossRef
24.
go back to reference Manuel O, Wojtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis. 2015;211(6):906–14.CrossRef Manuel O, Wojtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J Infect Dis. 2015;211(6):906–14.CrossRef
25.
go back to reference Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202(11):1749–53.CrossRef Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202(11):1749–53.CrossRef
26.
go back to reference Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D, et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS. 2011;25(2):269–71.CrossRef Rallon NI, Restrepo C, Naggie S, Lopez M, Del Romero J, Goldstein D, et al. Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. AIDS. 2011;25(2):269–71.CrossRef
27.
go back to reference Salgado M, Kirk GD, Cox A, Rutebemberwa A, Higgins Y, Astemborski J, et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS. 2011;25(3):385–7.CrossRef Salgado M, Kirk GD, Cox A, Rutebemberwa A, Higgins Y, Astemborski J, et al. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS. 2011;25(3):385–7.CrossRef
28.
go back to reference Real LM, Herrero R, Rivero-Juarez A, Camacho A, Macias J, Vic S, et al. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS. 2015;29(14):1895–7.CrossRef Real LM, Herrero R, Rivero-Juarez A, Camacho A, Macias J, Vic S, et al. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. AIDS. 2015;29(14):1895–7.CrossRef
29.
go back to reference Machmach K, Abad-Molina C, Romero-Sanchez MC, Dominguez-Molina B, Moyano M, Rodriguez MM, et al. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clin Microbiol Infect. 2015;21(3):289.CrossRef Machmach K, Abad-Molina C, Romero-Sanchez MC, Dominguez-Molina B, Moyano M, Rodriguez MM, et al. IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. Clin Microbiol Infect. 2015;21(3):289.CrossRef
30.
go back to reference Serrano-Villar S, Caruana G, Zlotnik A, Perez-Molina JA, Moreno S. The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naive HIV-infected individuals. Antimicrob Agents Chemother. 2017;61:e01763–817.CrossRef Serrano-Villar S, Caruana G, Zlotnik A, Perez-Molina JA, Moreno S. The effects of maraviroc versus efavirenz in combination with zidovudine/lamivudine on the CD4/CD8 ratio in treatment-naive HIV-infected individuals. Antimicrob Agents Chemother. 2017;61:e01763–817.CrossRef
31.
go back to reference Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007;8(3):254–61.CrossRef Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007;8(3):254–61.CrossRef
32.
go back to reference Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 2011;3(6):348–61.CrossRef Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med. 2011;3(6):348–61.CrossRef
33.
go back to reference Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008;125(4):492–502.CrossRef Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008;125(4):492–502.CrossRef
34.
go back to reference Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, et al. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clin Infect Dis. 2017;64(5):621–8.PubMedPubMedCentral Dominguez-Molina B, Tarancon-Diez L, Hua S, Abad-Molina C, Rodriguez-Gallego E, Machmach K, et al. HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clin Infect Dis. 2017;64(5):621–8.PubMedPubMedCentral
35.
go back to reference Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP. Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection. J Immunol. 2013;190(5):1991–2000.CrossRef Condotta SA, Rai D, James BR, Griffith TS, Badovinac VP. Sustained and incomplete recovery of naive CD8+ T cell precursors after sepsis contributes to impaired CD8+ T cell responses to infection. J Immunol. 2013;190(5):1991–2000.CrossRef
36.
go back to reference La Gruta NL, Thomas PG. Interrogating the relationship between naive and immune antiviral T cell repertoires. Curr Opin Virol. 2013;3(4):447–51.CrossRef La Gruta NL, Thomas PG. Interrogating the relationship between naive and immune antiviral T cell repertoires. Curr Opin Virol. 2013;3(4):447–51.CrossRef
37.
go back to reference Safrit JT, Fast PE, Gieber L, Kuipers H, Dean HJ, Koff WC. Status of vaccine research and development of vaccines for HIV-1. Vaccine. 2016;34(26):2921–5.CrossRef Safrit JT, Fast PE, Gieber L, Kuipers H, Dean HJ, Koff WC. Status of vaccine research and development of vaccines for HIV-1. Vaccine. 2016;34(26):2921–5.CrossRef
Metadata
Title
Interferon lambda rs368234815 ΔG/ΔG is associated with higher CD4+:CD8+ T-cell ratio in treated HIV-1 infection
Authors
Inês T. Freitas
Willard Tinago
Hirofumi Sawa
Julie McAndrews
Brenda Doak
Charlotte Prior-Fuller
Gerard Sheehan
John S. Lambert
Eavan Muldoon
Aoife G. Cotter
William W. Hall
Patrick W. G. Mallon
Michael J. Carr
Publication date
01-12-2020
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2020
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-020-00269-0

Other articles of this Issue 1/2020

AIDS Research and Therapy 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine